Search results
The Novartis “Managed Access” terminology covers all locally defined pre-approval access mechanisms and programs such as “Compassionate Use”, “Expanded Access”, “Named Patient Supply”, “Special Access Schemes/Programs”, “Autorisations temporaires d’utilisation (ATU)” and others.
- PDF
PDF - Managed access programs | Novartis
- PDF
The Novartis Gene Therapies global Managed Access Program (MAP) is designed to provide a potential pathway for patients seeking such a treatment, provided the required eligibility criteria are met and in accordance with applicable local laws and regulations.
Jan 9, 2023 · Since it first launched, we have worked to broaden global access to Zolgensma® (onasemnogene abeparvovec), closely collaborating with local governments and payors to craft innovative access solutions that enable eligible spinal muscular atrophy (SMA) patients to obtain the gene therapy.
Jan 24, 2022 · Today, we are proud to announce we have renewed the global MAP program with up to 100 doses again planned in 2022. This program benefits patients and families who otherwise would not have access to our gene therapy or other SMA treatments and is a particular point of pride for our organization.
The Novartis Gene Therapies “Managed Access Program” terminology covers all locally defined pre-approval access mechanisms and programs such as “Compassionate Use”, “Expanded Access”, “Named Patient Supply”, “Special Access Schemes/Programs”, “Autorisations temporaires d’utilisation (ATU)” and others.
Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting. Healthcare professionals
Patients with serious or life-threatening diseases or conditions sometimes seek medical products that are not yet approved or available in their country. Novartis “Managed Access” addresses this need by making certain investigational or unapproved treatments available to eligible patients.
